DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 204781
NDA 204781 describes DOTAREM, which is a drug marketed by Guerbet and is included in one NDA. It is available from one supplier. Additional details are available on the DOTAREM profile page.
The generic ingredient in DOTAREM is gadoterate meglumine. One supplier is listed for this compound. Additional details are available on the gadoterate meglumine profile page.
The generic ingredient in DOTAREM is gadoterate meglumine. One supplier is listed for this compound. Additional details are available on the gadoterate meglumine profile page.
Summary for 204781
| Tradename: | DOTAREM |
| Applicant: | Guerbet |
| Ingredient: | gadoterate meglumine |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 204781
| Mechanism of Action | Magnetic Resonance Contrast Activity |
Suppliers and Packaging for NDA: 204781
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781 | NDA | Guerbet LLC | 67684-2000 | N | 67684-2000-0 |
| DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781 | NDA | Guerbet LLC | 67684-2000 | N | 67684-2000-1 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 37.69GM/100ML (376.9MG/ML) | ||||
| Approval Date: | Mar 20, 2013 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Mar 20, 2018 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Regulatory Exclusivity Expiration: | Aug 25, 2020 | ||||||||
| Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3.769GM/10ML (376.9MG/ML) | ||||
| Approval Date: | Mar 20, 2013 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Mar 20, 2018 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Complete Access Available with Subscription
